Defunct Company
Total Trials
22
As Lead Sponsor
14
As Collaborator
8
Total Enrollment
8,878
NCT00945880
Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive
Phase: Phase 1
Role: Lead Sponsor
Start: Jul 31, 2009
Completion: Aug 31, 2010
NCT00916747
Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
Phase: Phase 2
Role: Collaborator
Start: Aug 31, 2009
Completion: Dec 31, 2023
NCT01316185
Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)
Start: Jan 31, 2011
Completion: Apr 30, 2013
NCT02430181
Lonafarnib With and Without Ritonavir in HDV (LOWR-1)
Start: Nov 30, 2014
Completion: Nov 30, 2015
NCT02430194
Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)
Start: Dec 31, 2014
Completion: Jun 15, 2017
NCT02527707
Titrating-Dose of Lonafarnib in Combination With Ritonavir
Start: Sep 30, 2015
Completion: Feb 9, 2017
NCT02664558
A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
Start: Apr 30, 2016
Completion: Jan 31, 2018
NCT02771574
Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia
Start: May 31, 2016
Completion: Jun 30, 2017
NCT02700529
Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)
Start: Jun 30, 2016
Completion: Feb 28, 2019
NCT02765802
A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection
Start: Oct 19, 2016
Completion: Dec 12, 2018
NCT02736149
Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
Start: Dec 31, 2016
Completion: Aug 31, 2018
NCT03373435
Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia
Start: Mar 19, 2018
Completion: Mar 15, 2019
NCT03719313
Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a
Phase: Phase 3
Start: Dec 1, 2018
Completion: Mar 24, 2023
NCT04343976
Pegylated Interferon Lambda Treatment for COVID-19
Start: Jun 22, 2020
Completion: Jul 30, 2021
NCT04344600
Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection
Start: Jun 29, 2020
Completion: Sep 24, 2021
NCT04388709
Interferon Lambda Therapy for COVID-19
Start: Sep 30, 2020
Completion: Feb 5, 2021
NCT04727424
Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms
Start: Jan 19, 2021
Completion: Jul 1, 2024
NCT05229991
Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection
Start: May 15, 2021
Completion: Apr 30, 2025
NCT04652479
Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia
Start: Jun 21, 2021
Completion: Jun 30, 2022
NCT05070364
Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV
Start: Dec 21, 2021
Completion: Jan 15, 2025